Bond JC, Abrams J, Wesselink AK, White KO, Rothman KJ, Wise LA. Predictors of non-response to a sexual health survey in a North American preconception cohort study. J Sex Med. 2022 Nov;19(11):1707-15. doi: 10.1016/j.jsxm.2022.08.199
John NM, Wright SJ, Gavan SP, Vass CM. The role of information provision in economic evaluations of non-invasive prenatal testing: a systematic review. Eur J Health Econ. 2019 Nov;20(8):1123-31. doi: 10.1007/s10198-019-01082-x
Mansfield C, Gebben D, Sutphin J, Tepper SJ, Schwedt TJ, Sapra S, Shah N. Patient preferences for preventive migraine treatments: a discrete-choice experiment. Headache. 2019 Mar;59(5):715-26. doi: 10.1111/head.13498
Hoffman V, Xue F, Green E, Eisele O, Kurth T, Seeger JD. Risk of cardiovascular events in migraine patients treated with prophylactic medications. Poster presented at the 59th Annual Scientific Meeting American Headache Society; June 8, 2017. Boston, MA. [abstract] Headache. 2017 Jun 7; 57(S3). doi: 10.1111/head.13102
Hoffman V, Xue F, Green E, Eisele O, Kurth T, Seeger JD. Risk of cerebrovascular events in migraine patients treated with prophylactic medications. Poster presented at the 59th Annual Scientific Meeting American Headache Society; June 8, 2017. Boston, MA. [abstract] Headache. 2017 Jun 7; 57(S3). doi: 10.1111/head.13102
Clark M, Schwedt TJ, Tepper SJ, Harris N, Martin S, Sapra S, Shah N. Patient satisfaction with prophylactic migraine medications. Poster presented at the 59th Annual Scientific Meeting American Headache Society; June 2017. Boston, MA. [abstract] Headache. 2017 Jun; 57(Suppl S3):133.
Wilson MR, Bergman A, Chevrou-Severac H, Selby R, Smyth M, Kerrigan MC. Cost-effectiveness of vedolizumab compared with infliximab, adalimumab, and golimumab in patients with ulcerative colitis in the United Kingdom. Eur J Health Econ. 2017 Mar;19(2):229-40. doi: 10.1007/s10198-017-0879-5.
Gonzalez JM, Johnson FR, Runken MC, Poulos CM. Evaluating migraineurs' preferences for migraine treatment outcomes using a choice experiment. Headache. 2013 Nov;53(10):1635-50.
Beard SM, von Scheele BG, Nuki G, Pearson IV. Cost-effectiveness of febuxostat in chronic gout. Eur J Health Econ. 2013 May;Advance online publication.
Coon CD, Fehnel SE, Davis KH, Runken MC, Beach ME, Cady RK. The development of a survey to measure completeness of response to migraine therapy. Headache. 2012 Apr 1;52(4):550-72.
Fehnel SE, Coon CD, Davis KH, Runken MC, Cady RK. Development and Psychometric Evaluation of the Migraine Completeness of Response Survey (CORS). Poster presented at the 52nd Annual Scientific Meeting of the American Headache Society; June 2010. [abstract] Headache. 2010 Aug; 50(s1):S49-50.
Johannes C, Odom D, Bennett L, Foley D. The impact of menopause status on formal vs. informal care-seeking behavior in women with decreased sexual desire with associated distress. J Sex Med. 2010 May 1;7(Suppl. 3):123.
Rosen RC, Shifren JL, Monz BU, Odom DM, Russo PA, Johannes CB. Correlates of sexually related personal distress in women with low sexual desire. J Sex Med. 2009 Jun 1;6(6):1549-60.
Greiner W, Lehmann K, Earnshaw S, Bug C, Sabatowski R. Economic evaluation of Durogesic in moderate to severe, nonmalignant, chronic pain in Germany. Eur J Health Econ. 2006 Dec 1;7(4):290-6.
Britt D, Kubin M, Keininger D, Trudeau E, Sagnier P, Beneke M. Development and validation of the treatment satisfaction scale (TSS) for erectile dysfunction. J Sex Med. 2003 Oct;25(Suppl 5):S180.
Lehmann K, Radbruch L, Gockel HH, Neighbors D, Nuyts G. Costs of opioid therapy for chronic nonmalignant pain in Germany: an economic model comparing transdermal fentanyl (Duragesic) with controlled release morphine. Eur J Health Econ. 2002;3:111-9. doi: 10.1007/s10198-002-0097-6.
Hartmaier SL, Demuro-Mercon C, Linder S, Winner P, Santanello NC. Development of a brief 24-hour adolescent migraine functioning questionnaire. Headache. 2001 Feb 1;41(2):150-6.